Ultragenyx Pharmaceutical Inc. (RARE) Position Held by Fortaleza Asset Management Inc

Adjust Comment Print

FMR LLC now owns 6,110,627 shares of the biopharmaceutical company's stock valued at $414,178,000 after buying an additional 227,802 shares during the last quarter. The stock rose 0.16% or $0.25 reaching $160.03 per share. About 63,312 shares traded. Twin Disc, Incorporated (TWIN) has risen 77.28% since August 23, 2016 and is uptrending. It has outperformed by 45.78% the S&P500. On August 23 the company was downgraded to "Hold" from "Buy" and a price target of $55.00 was set in a report from SunTrust Robinson Humphrey. Therefore 53% are positive. H. Lundbeck AS had 3 analyst reports since August 20, 2015 according to SRatingsIntel. Ultragenyx Pharmaceutical Inc (NDAQ:RARE) has declined 6.49% since August 23, 2016 and is downtrending.

Elsewhere, B Riley upgrade the stock to "buy" from "neutral" after hiking its price target to US$22 from US$18.50. Canaccord Genuity maintained it with "Buy" rating and $100 target in Friday, March 24 report. Ultragenyx Pharmaceutical has a consensus rating of "Hold" and a consensus target price of $83.50. H.C. Wainwright maintained Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Tuesday, August 8. Including today's unusual volume, Ultragenyx Pharmaceutical Inc.'s stock is performing at -16.30% on the year. The rating was initiated by Stifel Nicolaus on Tuesday, December 1 with "Buy". Lowers Ultragenyx Pharmaceutical Inc. RBC Capital Markets has "Buy" rating and $7600 target. Putnam Investments invested 0.01% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.14, from 1.21 in 2016Q3. It fall, as 17 investors sold Ultragenyx Pharmaceutical Inc shares while 56 reduced holdings. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has "Outperform" rating given on Thursday, January 21 by Credit Suisse. Macquarie Grp Limited stated it has 0% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Legal & General Group Plc now owns 15,082 shares of the biopharmaceutical company's stock valued at $933,000 after buying an additional 2,212 shares during the period. Aureus Asset Management Ltd Liability reported 4,900 shares stake.

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Rhumbline Advisers owns 41,628 shares. Employees Retirement Association Of Colorado holds 0% or 6,773 shares in its portfolio. Bancorp Of Mellon reported 0% stake.

Senate hearing on the death of Kian delos Santos
The three policemen involved in the incident were relieved from their positions while the investigation is being conducted. Aguirre retorted: "I sympathize with you, being the representative of Kabataan ay totoo po yang sinasabi ninyo".


Iguana Healthcare Management Llc increased Scynexis Inc (NASDAQ:SCYX) stake by 125,000 shares to 250,000 valued at $798,000 in 2016Q4. Brown Advisory accumulated 298,243 shares. Natl Pension Ser holds 0.3% or 761,884 shares. 8,559 are owned by Allianz Asset Mgmt Ag. Dekabank Deutsche Girozentrale holds 27,820 shares or 0.02% of its portfolio.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 58.85 on Wednesday. It also upped Spdr S&P 500 Etf Tr (SPY) stake by 3,343 shares and now owns 37,979 shares.

Ultragenyx Pharmaceutical (NASDAQ:RARE) was lowered by SunTrust Banks, from a "buy" recommendation to a "hold" recommendation in a research note released to investors and clients on early Wednesday. Shares in Ultragenyx, which has a market cap of $2.5 billion, were down 14% in premarket trading. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. It now has negative earnings. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Shares for $1.86M were sold by Riccio Daniel J. on Wednesday, June 7. Maestri Luca sold $2.51M worth of stock. 75,000 Apple Inc. (NASDAQ:AAPL) shares with value of $11.10 million were sold by AHRENDTS ANGELA J. Another trade for 35,000 shares valued at $5.39 million was sold by LEVINSON ARTHUR D.

Comments